Safe and effective use of the once weekly dulaglutide single-dose pen in Injection-Naïve patients with type 2 diabetes

Journal of Diabetes Science and Technology

Volumn 9, Issue 5, 2015, Pages 1071-1079

  Matfin, Glenn ^a   Van Brunt, Kate ^b   Zimmermann, Alan G ^b   Threlkeld, Rebecca ^b   Ignaut, Debra A ^b  

^a INTERNATIONAL DIABETES CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Dulaglutide; Self injection; Single dose pen; Type 2 diabetes

Indexed keywords

DULAGLUTIDE; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT;

ADULT; ARTICLE; CLINICAL OUTCOME; CONTUSION; DEVICE SAFETY; FEMALE; HEADACHE; HUMAN; INJECTION PAIN; INJECTION PEN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE MASS; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PATIENT-REPORTED OUTCOME; QUESTIONNAIRE; RHINOPHARYNGITIS; SELF INJECTION; SINUS CONGESTION; SINUSITIS; TRAINING; UPPER RESPIRATORY TRACT INFECTION; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; PATIENT PREFERENCE; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PATIENT PREFERENCE; PATIENT SATISFACTION; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 85018214785     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/1932296815583059     Document Type: Article

References (26)

1. Peyrot M, Matthews DR, Snoek FJ, et al. An international study of psychological resistance to insulin use among persons with diabetes. Diabetologia. 2003; 46(SUPPL. 2):A89.
2. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005; 28:2673-2679.
3. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002; 26 (suppl 3):S18-S24.
4. An J, Nichol MB. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013; 51:879-887.
5. Hornsten A, Lundman B, Selstam EK, Sandstrom H. Patient satisfaction with diabetes care. J Adv Nurs. 2005; 51:609-617.
6. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin. 2009; 25:1413-1420.
7. Lee WC, Balu S, Cobden D, Joshi AV, Pashos CL. Prevalence and economic consequences of medication adherence in diabetes: a systematic literature review. Manag Care Interface. 2006; 19:31-41.
8. Ingersoll KS, Cohen J. The impact of medication regimen factors on adherence to chronic treatment: a review of literature. J Behav Med. 2008; 31:213-224.
9. Peyrot M, Rubin RR, Kruger DF, Travis LB. Correlates of insulin injection omission. Diabetes Care. 2010; 33:240-245.
10. Ross SA. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes. Am J Med. 2013; 126(9 suppl 1):S38-S48.
11. Korytkowski M, Niskanen L, Asakura T. FlexPen: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005; 27:S89-S100.
12. Molife C, Lee LJ, Shi L, Sawhney M, Lenox SM. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. Diabetes Technol Ther. 2009; 11:529-538.
13. Rex J, Jensen KH, Lawton SA. A review of 20 years' experience with the NovoPen family of insulin injection devices. Clin Drug Investig. 2006; 26:367-401.
14. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004; 27:2495-2497.
15. Mollema ED, Snoek FJ, Pouwer F, Heine RJ, van der Ploeg HM. Diabetes Fear of Injecting and Self-Testing Questionnaire: a psychometric evaluation. Diabetes Care. 2000; 23: 765-769.
16. Snoek FJ, Mollema ED, Heine RJ, Bouter LM, van der Ploeg HM. Development and validation of the Diabetes Fear of Injecting and Self-Testing Questionnaire (D-FISQ): first findings. Diabet Med. 1997; 14:871-876.
17. Szeinbach SL, Barnes JH, Summers KH, Lenox SM. Development of an instrument to assess expectations of and preference for an insulin injection pen compared with the vial and syringe. Clin Ther. 2004; 26:590-597.
18. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci. 2001; 16:101-133.
19. Lorenzi G, Schreiner B, Osther J, Boardman M. Application of adult-learning principles to patient instructions: a usability study for an exenatide once-weekly injection device. Clin Diabetes. 2010; 28:157-162.
20. Davis EM, Bebee A, Crawford L, Destache C. Nurse satisfaction using insulin pens in hospitalized patients. Diabetes Educ. 2009; 35:799-809.
21. Asakura T, Jensen KH. Comparison of intuitiveness, ease of use, and preference in two insulin pens. J Diabetes Sci Technol. 2009; 3:312-319.
22. Nadeau DA, Campos C, Niemeyer M, Bailey T. Healthcare professional and patient assessment of a new prefilled insulin pen versus two widely available prefilled insulin pens for ease of use, teaching and learning. Curr Med Res Opin. 2012; 28: 3-13.
23. McKay M, Compion G, Lytzen L. A comparison of insulin injection needles on patients' perceptions of pain, handling, and acceptability: a randomized, open-label, crossover study in subjects with diabetes. Diabetes Technol Ther. 2009; 11: 195-201.
24. Heise T, Nosek L, Dellweg S, et al. Impact of injection speed and volume on perceived pain during subcutaneous injections into the abdomen and thigh: a single-centre, randomized controlled trial. Diabetes Obes Metab. 2014; 16:971-976.
25. Phillips JT, Fox E, Grainger W, Tuccillo D, Liu S, Deykin A. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011; 11:126-134.
26. D'Arcy C, Thomas D, Stoneman D, Parkes L. Patient assessment of an electronic device for subcutaneous self-injection of interferon ß-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Prefer Adherence. 2012; 6:55-61.